Business
60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston
60 Degrees Pharmaceuticals will present scientific poster on new, long-term safety data on the use of tafenoquine for malaria prevention at the ILADS 2023
About this update from 60 Degrees Pharmaceuticals, Inc.
[{"type":"text","content":"60 Degrees Pharmaceuticals will present scientific poster on new, long-term safety data on the use of tafenoquine for malaria prevention at the ILADS 2023 annual scientific meeting60 Degrees Pharmaceuticals will also present a comprehensive review of the scientific literature on the use of 8-aminoquinolines in treating malaria and babesiosis in a sponsored symposium at ILADS, 2023 WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, will present a poster titled, “Long-term safety of the tafenoquine antimalarial chemoprophylaxis regimen, a 12-month, randomized double-blind placebo-controlled trial” at the International Lyme & Associated Diseases Society (ILADS) annual conference in Boston on October 21, 2023. The poster will be presented by 60 Degrees Pharmaceuticals Chief Executive Officer, Geoff Dow, PhD. Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA®. The safety of the approved regimen of tafenoquine for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for durations of up to six months. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the FDA for such indications. The sponsored symposium will feature a comprehensive review of the use of 8-aminoquinolines in treating malaria and babesiosis. The efficacy and safety of 8-aminoquinolines, a class of drugs that includes tafenoquine and primaquine, for prevention and treatment of malaria is well established. The appearance of several case studies of tafenoquine use for babesiosis in the literature suggests that the drug is being used for this purpose in practice of medicine; the Company is planning an adequate and well controlled clinical study to evaluate this use more systematically. About Babesiosis An estimated 47,000 cases of babesiosis (infections caused by red blood cell parasites similar to malaria that are transmitted by deer tick bites) occur in the United States each year, and the incidence rate is increasing. Estimates are that 10 percent of Lyme disease patients are co-infected with babesiosis. The mortality rate of bab...